Mr Peter Nolan
Oxford BioMedica (LSE:OXB) is a leading gene therapy and immunotherapy company with a platform of exclusive and pioneering technologies to design, develop and manufacture unique gene-based medicines. The Company’s technology platforms include a highly efficient LentiVector® gene delivery system; a single administration to provide long-lasting therapy with specific advantages for targeting CNS and ocular diseases, and a unique tumour antigen (5T4) which is an ideal target for anti-cancer therapy.
The Company’s pipeline addresses diseases for which there is currently no treatment or that are inadequately treated today, including ocular diseases, neurodegenerative disorders and cancer, and its product candidates have the potential to transform treatment landscapes. Oxford BioMedica’s capabilities cover the entire product lifecycle, from research to development to GMP manufacturing, with collaborative partners such as Sanofi, Pfizer, Novartis and some of the most prestigious clinical centres worldwide. The Company recently secured significant funding via UK Government competitive awards such as the TSB regenerative medicine/cell therapy grant and AMSCI to build a centre of excellence for specialist manufacture of gene-based therapies.
Through in-house development programmes and industry collaborations, Oxford BioMedica’s goal is to improve the lives of patients with debilitating and life-threatening diseases. Further information is available at www.oxfordbiomedica.co.uk and www.oxbsolutions.co.uk.